<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399643</url>
  </required_header>
  <id_info>
    <org_study_id>ML39704</org_study_id>
    <nct_id>NCT03399643</nct_id>
  </id_info>
  <brief_title>A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)</brief_title>
  <acronym>Announce</acronym>
  <official_title>Non-Interventional Study To Investigate The Effectiveness Of Atezolizumab Under Real-World Conditions In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the effectiveness of Atezolizumab with a
      primary focus on the overall survival (OS) rate at 2 years and secondary focuses on quality
      of life (QoL) and the sequence of treatment in mUC patients. Furthermore, this study aims at
      collecting data on safety of Atezolizumab and on the reason for cisplatin-ineligibility
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Tecentriq label restriction for first line limited the patient population and scientific
    question could not be answered in an appropriate time.
  </why_stopped>
  <start_date type="Actual">December 28, 2017</start_date>
  <completion_date type="Actual">January 28, 2019</completion_date>
  <primary_completion_date type="Actual">August 28, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival Rate (OS rate)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS)</measure>
    <time_frame>Initiation of study treatment until death or end of study, approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival (PFS)</measure>
    <time_frame>Initiation of study treatment to first measured disease progression, through end of study (approximately 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with adverse events</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">22</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab is administered via IV 1200 mg every 3 weeks</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of patients ineligible for palliative cisplatin-based
        chemotherapy or who received prior adjuvant/ neoadjuvant chemotherapy or chemo radiation
        with a treatment-free interval more than 12 months (1L)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic UC (Urothelial Carcinoma) including cancers of the renal pelvis, ureters,
             urinary bladder, and urethra

          -  Will be receiving atezolizumab for the treatment of inoperable locally-advanced or
             metastatic UC, per the decision of the treating physician

          -  Have adequate hematologic and end-organ functions

          -  Have had no prior palliative chemotherapy for inoperable locally-advanced or
             metastatic UC and are clinically ineligible (&quot;unfit&quot;) for cisplatin-based chemotherapy

        Exclusion Criteria:

          -  Have received prior immune checkpoint therapy

          -  Are pregnant or breastfeeding

          -  Are included in any other trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis Dr.med. Wolfgang Hölzer</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie Schlosscarree</name>
      <address>
        <city>Braunschweig</city>
        <zip>38100</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis Dr. Krieger</name>
      <address>
        <city>Chemnitz</city>
        <zip>09127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zeisigwaldkliniken Bethanien</name>
      <address>
        <city>Chemnitz</city>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Georg Klinikum Eisenach GmbH</name>
      <address>
        <city>Eisenach</city>
        <zip>99817</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Franziskus-Hospital; Malteser Krankenhaus; Medizinische Klinik I</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst GmbH; Klinik Innere Medizin 3 - Hämatologie, Onkologie, Palliativmedizin</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres.Jochen Wilke und Harald Wagner</name>
      <address>
        <city>Fürth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis Michael Steinacker</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona, Abteilung für Urologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis in Heidenheim</name>
      <address>
        <city>Heidenheim</city>
        <zip>89522</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bernward-Krankenhaus</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Landshut</name>
      <address>
        <city>Landshut</city>
        <zip>84036</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis; Onkologisches Zentrum Lebach; Caritas Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ÜBAG MVZ Mitte / MVZ Delitzsch GmbH, Standort Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sankt Elisabeth Krankenhaus; Urlogische Abt.</name>
      <address>
        <city>Leipzig</city>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drk Krankenhaus Luckenwalde</name>
      <address>
        <city>Luckenwalde</city>
        <zip>14943</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Urologie</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologikum Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23566</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologischen Praxis in Lüneburg</name>
      <address>
        <city>Lüneburg</city>
        <zip>21335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät Mannheim, Universitätsklinikum Mannheim, Klinik für Urologie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Markkleeberg</name>
      <address>
        <city>Markkleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mühlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik für Hämatologie, Onkologie und Pallia.</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt.Kliniken München GmbH Klinikum Bogenhausen</name>
      <address>
        <city>München</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Uhlig, Naunhof</name>
      <address>
        <city>Naunhof</city>
        <zip>04683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef Paderborn, Klinik für Hämatologie/Onkologie</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie &amp; Onkologie</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken</name>
      <address>
        <city>Stade</city>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier; Innere Medizin I, Hämatologie / Internistische Onkologie</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Wedel</city>
        <zip>22880</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie Westerstede Aurich Rhauder</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

